[{"id":"0774e5dd-f070-4a40-b5a3-4bcf55f2b730","acronym":"","url":"https://clinicaltrials.gov/study/NCT03178071","created_at":"2021-01-17T17:11:22.643Z","updated_at":"2024-07-02T16:36:54.005Z","phase":"","brief_title":"Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive","source_id_and_acronym":"NCT03178071","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement • ROS1 positive • ROS1 rearrangement • ALK G1202R","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement • ROS1 positive • ROS1 rearrangement • ALK G1202R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2019-11-04"}]